ERBB2 and breast cancer: In this single-institution study with 10-year follow-up, we demonstrated that patients with early-stage ER-positive HER2(-) breast cancer, RS < 16, and mostly presenting with lymph node-negative breast cancer have excellent prognosis with endocrine treatment alone without any locoregional recurrence.